GlassScriptPhysician profile
Elion Jeffrey Krok
NPI 1538468491
$1,282.80
in general payments reported to CMS, 2019-2025
12 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $196 · 2021: $265 · 2022: $394 · 2023: $117 · 2024: $56.01 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $292.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $557.14 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $167.54 | 2020-2024 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $157.08 | 2020-2025 | Gattex |
| Endo Pharmaceuticals INC. | $103.50 | 2020-2022 | |
| Abbvie INC. | $83.95 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $69.00 | 2020-2025 | Contrave |
| Shire North American Group INC | $41.28 | 2019 | |
| Vivus LLC | $30.09 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.54 | 2022 | |
| Dexcom, INC. | $20.55 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.48 | 2023 | |
| Allergan, INC. | $12.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elion Krok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.